Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Achieve Life Sciences clinical trials
Also known as OncoGenex, Sonus.
The registry lists 31 studies whose lead sponsor is Achieve Life Sciences. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 15, 2026.
Keep track of what changes. Save the Achieve Life Sciences studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Achieve Life Sciences.
- Achieve Life Sciences31 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 31 of 31.
- Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesNot yet recruitingNCT07392125Phase 3
- A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerCompletedNCT01630733Phase 3
- A Study of Cytisinicline for Smoking Cessation in Adult SmokersCompletedNCT04576949Phase 3
- A Second Study of Cytisinicline for Smoking Cessation in Adult SmokersCompletedNCT05206370Phase 3
- A Study of Cytisinicline for Vaping Cessation in Adult SmokersCompletedNCT05431387Phase 2
- Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette SmokersCompletedNCT06435221Phase 3
- Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline DoseCompletedNCT05631938Phase 1
- Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult SmokersCompletedNCT05981768Phase 1
- Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy SmokersCompletedNCT05566288Phase 1
- A Single Dose-escalation Study of Cytisine in Adult SmokersCompletedNCT03848208Phase 1
- Trial of Cytisine in Adult SmokersCompletedNCT03709823Phase 2
- A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy SmokersTerminatedNCT03303911Phase 1/2
- A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New FormulationCompletedNCT03509948Phase 1
- A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of CytisineCompletedNCT03268343Phase 1
- Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerCompletedNCT01188187Phase 3
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerCompletedNCT01578655Phase 3
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedNCT01083615Phase 3
- Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationCompletedNCT01874561Phase 1
- A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenCompletedNCT01497470Phase 1
- A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder CancerCompletedNCT01454089Phase 2
- Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder CancerCompletedNCT00487786Phase 1
- Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCCompletedNCT00327340Phase 2
- A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00138658Phase 1/2
- Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast CancerCompletedNCT00096668Phase 2
- Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast CancerTerminatedNCT00251095Phase 3
- Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung CancerCompletedNCT00034164Phase 2
- Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal AdenocarcinomaCompletedNCT00034190Phase 2
- TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumCompletedNCT00077688Phase 2
- Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the UrotheliumCompletedNCT00034177Phase 2
- Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian CancerCompletedNCT00034151Phase 2
- Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid TumorsCompletedNCT00385177Phase 1